menu ☰
menu ˟

[Correspondence] Drawing conclusions from the VIVA trial

12 May 2018

The VIVA trial by Jes Lindholt and Rikke Søgaard (Nov 18, 2017, p 2256)1 assessed the effects of screening for abdominal aortic aneurysm, peripheral arterial disease, and hypertension, showing a small but statistically significant reduction in total mortality in the screening group versus the non-screening group. The authors concluded that “the observed reduction of mortality risk from abdominal aortic aneurysm, peripheral arterial disease, and hypertension” should lead policy makers to “consider implementing combined screening”.

Click here to view the full article which appeared in The Lancet

IPH Logo